Welcome to our dedicated page for Monte Rosa Therapeutics SEC filings (Ticker: GLUE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Monte Rosa Therapeutics filings document a clinical-stage biotechnology company developing molecular glue degrader medicines and reporting as a Nasdaq-listed operating company. Its 8-K filings cover financial results, Regulation FD clinical disclosures, material-event updates and capital-structure matters tied to common stock and registration statements.
The company’s proxy materials disclose annual meeting proposals, director elections, auditor ratification and governance practices. Other filings address executive officer and principal accounting officer transitions, compensatory arrangements, shareholder voting matters, clinical program disclosures for MRT-8102 and MRT-2359, and risk areas associated with drug development, financing and public-company compliance.
Monte Rosa Therapeutics President & CEO Markus Warmuth reported an open-market sale of 5,466 shares of common stock at a weighted average price of $17.9243 per share on March 2, 2026. The trades occurred between $17.50 and $18.46 under a pre-arranged Rule 10b5-1 trading plan adopted on May 14, 2025. After these transactions, he directly holds 613,471 shares of Monte Rosa Therapeutics common stock.
GLUE submitted a Rule 144 notice reporting proposed sales of its common stock traded on NASDAQ. The filing notes an RSU vest on 03/03/2026 tied to equity compensation and lists recent trades by Edmund Dunn: 1,039 shares on 01/05/2026 for $15,762.65, 25,164 shares on 02/27/2026 for $455,506.15, and 536 shares on 03/02/2026 for $9,380.
Monte Rosa Therapeutics principal accounting officer Edmund Dunn reported option exercises paired with share sales. On February 27 and March 2, 2026, he exercised stock options to acquire common shares at an exercise price of $13.41 per share.
He then sold a total of 25,700 common shares in open-market transactions, including a weighted-average sale price of $18.1015 per share for one block and $17.50 per share for another. After these trades, Dunn directly owned 22,693 Monte Rosa Therapeutics shares.
Form 144 filing reporting proposed sales and recent transactions by Markus Warmuth. The excerpt lists a proposed sale entry showing Common security lines and an RSU stock award granted 01/02/2025 with a related date 01/02/2026. The filing shows prior sales in the past three months with amounts 128372.00 and 153759.00 tied to Markus Warmuth, and an additional numeric line 97974.00 associated with a common security entry. The filing names Monte Rosa Therapeutics Inc and lists an address for Mr. Warmuth in Boston.
Morgan Stanley Smith Barney LLC Executive Financial Services filed a Form 144 disclosing the proposed sale of 536 common shares by means of a stock option exercise on 03/02/2026. The filing lists cash proceeds as the method of settlement.
The excerpt also reports recent open-market sales by Edmund Dunn of 25,164 shares for $455,506.15 on 02/27/2026 and 1,039 shares for $15,762.65 on 01/05/2026.
Issuer files a Form 144 reporting proposed sale of 25,164 common shares. The filing lists the transaction type as a Stock Option Exercise with a sale date of 02/27/2026. It also shows prior shares sold of 1,039 on 01/05/2026 for $15,762.65.
Monte Rosa Therapeutics Chief Medical Officer Filip Janku reported an open-market sale of company stock. On February 23, 2026, he sold 9,189 shares of common stock at an average price of $19.4973 per share and now directly owns 65,837 shares.
GLUE insider notice to sell common stock. Filip Janku filed a Form 144 reporting a proposed sale of 3,155 common shares on 01/05/2026 with an aggregate value of $47,863.58.
The filing lists prior ESPP-related share lots with dates and share counts (12/29/2023: 1,282; 12/30/2022: 1,820; 06/30/2023: 2,150; 06/28/2024: 3,937). These rows describe securities and dates as shown in the excerpt.
Monte Rosa Therapeutics, Inc. received an updated ownership report from a group of investment entities associated with Biotechnology Value Fund and Mark N. Lampert. As of December 31, 2025, these Reporting Persons may be deemed to beneficially own a total of 3,835,886 shares of Monte Rosa common stock, representing approximately 5.9% of the 65,117,761 shares outstanding as of October 31, 2025. Individual funds hold portions of this stake, including 2,050,405 shares at Biotechnology Value Fund, 1,496,859 shares at Biotechnology Value Fund II, and 232,097 shares at Biotechnology Value Trading Fund OS. The filing states the shares were not acquired and are not held for the purpose of changing or influencing control of the company.
Baker Bros. Advisors and affiliates report a 6.7% ownership stake in Monte Rosa Therapeutics, Inc. (GLUE) common stock. They beneficially own 4,345,736 shares based on 65,117,761 shares outstanding as of October 31, 2025, as cited from the company’s Form 10-Q.
The stake is held through two investment funds: 667, L.P. with 343,372 shares (0.5% of the class) and Baker Brothers Life Sciences, L.P. with 4,002,364 shares (6.2% of the class). Baker Bros. Advisors LP has discretion over investment and voting decisions, and the filing is certified as being made in the ordinary course of business without intent to influence control.